When did Tarsus Pharmaceuticals, Inc. report Q4 2024 earnings?

Tarsus Pharmaceuticals, Inc. (TARS) reported Q4 2024 earnings on February 25, 2025 before market open.

What were Tarsus Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?

Tarsus Pharmaceuticals, Inc. reported revenue of $66.4M and eps of $-0.60 for Q4 2024.

Did Tarsus Pharmaceuticals, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $64.5M by $2.0M. EPS beat the consensus estimate of $-0.68 by $0.08.

Where can I find Tarsus Pharmaceuticals, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001819790-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.

Tarsus Pharmaceuticals, Inc. TARS Q4 2024 Annual earnings

Reported February 25, 2025 · Before market open

Revenue$66.4MBeat by $2.0M

EPS-$0.60Beat by $0.08

Revenue estimate$64.5M

EPS estimate-$0.68

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$169.1M

EPS estimate-$0.21

Financials

Q4 2024

Income statement

See full

Revenue$66.4M+408%

Operating income-$24.4M+45.1%

Net income-$23.1M+44.8%

EPS (diluted)-$0.59+53.5%

Balance sheet

See full

Cash & equivalents$97.4M-56.7%

Total debt$72.5M+128%

Total equity$224.5M+14.0%

Total assets$377.0M+42.0%

Cash flow

See full

Operating cash flow-$22.2M+43.6%

CapEx$72.0K—

Free cash flow-$22.3M+43.4%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$2.12B+227%

Enterprise value$2.09B+361%

P/S11.6×-25.5×

Profitability

See full

Operating margin-65.9%-31.6pp

Net margin-63.2%-30.2pp

FCF margin-46.2%-22.3pp

Returns & leverage

See full

Return on equity-54.8%-9.6pp

Debt / equity0.3×+0.2×

Current ratio4.4×-2.5×

Segments

By segment

See full

Reportable Segment$66.4M+1,423%

Versus estimates

Revenue

Q1 2026$162.1MBeat by $12.5M Q4 2025$151.7MBeat by $7.1M Q3 2025$118.7MMiss by $25.9M Q2 2025$102.7MMiss by $10.4M Q1 2025$78.3MMiss by $20.8M

Q4 2024$66.4MBeat by $2.0M

Diluted EPS

Q1 2026-$0.16Beat by $0.24 Q4 2025-$0.20Miss by $0.10 Q3 2025-$0.30Beat by $0.05 Q2 2025-$0.48Miss by $0.15 Q1 2025-$0.64Beat by $0.05

Q4 2024-$0.60Beat by $0.08

Ask the moment Tarsus Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Tarsus Pharmaceuticals, Inc. report Q4 2024 earnings?: Tarsus Pharmaceuticals, Inc. (TARS) reported Q4 2024 earnings on February 25, 2025 before market open.
What were Tarsus Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?: Tarsus Pharmaceuticals, Inc. reported revenue of $66.4M and eps of $-0.60 for Q4 2024.
Did Tarsus Pharmaceuticals, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $64.5M by $2.0M. EPS beat the consensus estimate of $-0.68 by $0.08.
Where can I find Tarsus Pharmaceuticals, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001819790-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.